

34 Methodology: PPSP, AACS, RMFA, DOP
35 Project Administration: PPSP
36 Supervision: PPSP, AACS, RMFA, DOP, MMBMA
37 Writing – Original Draft Preparation: PPSP, AACS, RMFA, DOP, MMBMA, VAS, MSA,
38 ASB, SFR, EBS
39 Writing – Review & Editing: PPSP, AACS, RMFA, DOP, MMBMA, VAS, MSA, ASB,
40 SFR, EBS

41 ***Major outbreak of endophthalmitis after cataract***
42 ***surgery: a retrospective cohort in northern Brazil***

43 **Summary**

44 **Background:** Endophthalmitis is one of the most important adverse events after cataract
45 surgery as it can lead to total vision loss. The aim of this study was to describe the occurrence
46 of endophthalmitis after phacoemulsification with intraocular lens implantation among
47 patients assisted during a joint effort in Porto Velho, Rondônia, Brazil. **Method:** This is a
48 retrospective cohort study, carried out from a bank with 649 medical records of patients who
49 underwent surgery. Descriptive analysis and multiple analysis using Robust Poisson
50 Regression were performed to estimate relative risks (RR) and 95% confidence intervals
51 (95%CI). A statistical analysis was performed using the statistical program Stata® version
52 16.0 (College Station, Texas, USA). **Results:** The incidence of postoperative endophthalmitis
53 confirmed by culture was 10.88%, the highest ever recorded in the world. A higher risk for
54 endophthalmitis was found, in probable cases, among males (RR: 1.88; 95%CI:1.03; 3.44)
55 and brown and yellow skin color (RR: 2.78; 95 %CI %: 1.17; 6.60). For confirmed and
56 probable cases, bilateral surgery and specific lens model were also risk factors. The
57 predominant etiological agents were gram-negative and the main clinical manifestation was
58 corneal edema. The average number of days to start treatment was eight days and 27.12%
59 used antibiotics. **Conclusion:** Specific protocols are needed for cataract surgeries that
60 encompass hiring, performing and monitoring these services to ensure good practices and
61 patient safety.

62 **Key words:** Endophthalmitis; Disease Outbreaks; Cataract Surgery.

63 **Introduction**

64 Cataracts are responsible for up to 50% of cases of blindness in the world^[1]. It is
65 defined as any clouding of the lens with or without a decrease in visual acuity. Advanced age,
66 exposure to sunlight, comorbidities, previous eye diseases, ocular trauma, socioeconomic

67 status and the region where the individual resides are factors that directly or indirectly
68 interfere with the appearance of cataracts^[2].

69 To recover the visual capacity of the senile cataract carrier, surgery is the only option,
70 since the treatment with prescription glasses is transitory. Facectomy, associated with the
71 implantation of an intraocular lens, is a safe and effective procedure, providing visual
72 rehabilitation in the vast majority of cases^[3].

73 One of the main complications of facectomy is endophthalmitis. Its clinical
74 presentation usually occurs between one and seven days after surgery, but following the
75 recommendations of the Brazilian Ministry of Health, surveillance in search of symptoms and
76 symptoms suggestive of infection must occur within 90 days after the procedure when lens
77 implants were used^[4]. The main signs and symptoms of endophthalmitis are conjunctival
78 hyperemia, hypopyon, cloudy vitreous, anterior chamber reaction, corneal edema and loss of
79 visual acuity^[4].

80 Endophthalmitis must be recognized early, as in severe cases it can lead to
81 blindness^[5]. In addition to clinical consequences, there are also consequences in relation to the
82 individual's functional capacity, such as difficulty in carrying out daily activities and mental
83 outcomes such as isolation, sadness, irritability and even depression^[3]. As for health service
84 costs, a study conducted in the United States of America found that the occurrence of
85 endophthalmitis after cataract surgery increased 83% of expenses with reimbursements when
86 compared to those who did not develop the complication, which corresponded to the year
87 from 2014 to \$4,893 USD^[6].

88 In most cases, endophthalmitis is caused by the presence of bacteria found on the
89 palpebral margin and tear film of the patient's conjunctival flora^[7]. Other possible sources of
90 infection may be the contamination of equipment, instruments, supplies, solutions, surgical
91 drapes, lenses, or lack of good practice by health professionals^[7, 8].

92 According to a study carried out in Poland, after more than one million facectomy
93 surgeries, in a period of five years, the incidence rate of endophthalmitis was 0.066%^[9].
94 Another study conducted in Korea between 2014 and 2017, involving nearly one million
95 patients, found an incidence of 0.063%^[10]. In the United States, a survey of more than eight
96 million cataract removal surgeries found an incidence of 0.04%^[11]. In Malaysia, a cohort from
97 2008 to 2014 reported an incidence of 0.08%^[12]. In Brazil, in a study conducted between 2008
98 and 2014, after more than 27,000 cataract surgeries, the incidence was 0.13%, with an annual
99 variation of 0.04% to 0.27%^[2]. Another Brazilian study conducted in a northern Brazilian
100 state found that after 3,999 procedures performed in 2013 and 2014 in joint efforts, 1.67% had
101 perioperative or postoperative complications^[13].

102 To compensate for the appearance of new cases of cataracts and reduce the alarming
103 number of existing cases, it is estimated that it would be necessary to perform approximately
104 550,000 cataract surgeries in Brazil per year. In order to improve the access of the Brazilian
105 population, mainly in the most distant regions, to minimize budgetary and managerial
106 limitations, joint efforts are carried out^[13]. Mutirão is the Portuguese term that refers to the
107 organization of national campaigns for elective surgeries with the purpose of reducing queues
108 and waiting time for procedures^[1].

109 In the period from 02/14/2022 to 02/23/2022 in the municipality of Porto Velho, one
110 of the capitals of the northern region of Brazil, there was a joint effort of cataract surgeries.
111 On 02/23/2022, in the outpatient care of patients undergoing procedures, the first suspected
112 case of endophthalmitis was identified. On the same day, the surgeries were suspended by the
113 company responsible for the task force. After initial investigation of the cases by the Center
114 for Strategic Information on Health Surveillance of the State of Rondônia, an outbreak of
115 endophthalmitis was confirmed. Thus, the aim of this study is to describe the occurrence of

116 endophthalmitis after phacoemulsification with intraocular lens implantation among patients
117 assisted during a joint effort in Porto Velho, Rondônia, Brazil.

118 **Method**

119 Retrospective cohort study, carried out from a database with 649 medical records of
120 patients who underwent phacoemulsification surgery with intraocular lens implantation in the
121 city of Porto Velho, Rondônia, Northern Brazil. Some patients underwent bilateral surgery, so
122 there were 1,044 procedures in a period of 10 days, with an average of 104 procedures per day
123 (minimum 90 and maximum 120 procedures).

124 The State of Rondônia is located in the North Region of Brazil and is composed of 52
125 municipalities with an estimated population in 2021 of 1,815,278 inhabitants. About 73% of
126 the state's population lives in urban areas, the Human Development Index (HDI) was 0.690
127 and 6.02% of the population is over 60 years old^[14].

128 Information was collected from the medical records of users who underwent the
129 Phacoemulsification procedure with implantation of an intraocular lens from February 14 to
130 23, 2022 during an ophthalmological surgeries campaign in Porto Velho. The information was
131 typed into a standardized electronic form and the researchers were previously trained. The
132 information collected was: sociodemographic; previous exams; past pathological history;
133 materials and methods used in the procedure; signs and symptoms after the procedure;
134 examinations and treatment after the procedure. Not all the collected variables were used in
135 this initial analysis, it was decided to present in this article the variables with greater statistical
136 or epidemiological relevance already known.

137 A probable case was defined as an individual undergoing the procedure who
138 presented at least two of the following signs and symptoms: low visual acuity, ocular pain,
139 corneal edema, conjunctival hyperemia, hypopyon, anterior chamber reaction, cloudy vitreous
140 and/or patient submitted to postoperative intravitreal antimicrobial injection^[4]. Individuals

141 submitted to the procedure and with a laboratory diagnosis with a positive culture result in
142 vitreous and/or aqueous humor were considered as confirmed cases^[4]. The two case
143 definitions were chosen because using only culture-proven cases could lead to
144 underestimation of the reported true incidence^[15].

145 Data were presented in the form of absolute and relative frequencies and measures of
146 central tendency were used for numeric variables. Pearson's chi-square test (χ^2) and Fisher's
147 exact test were performed in the bivariate analysis. After bivariate analysis, the covariates
148 were tested for the presence of multicollinearity, represented by correlations greater than 0.80.
149 All variables with a significance level of 10% or epidemiological relevance were considered
150 as adjustment variables and submitted to multiple analysis.

151 The multiple analysis performed was Poisson Robust Regression to estimate relative
152 risks (RR) and 95% confidence intervals (95%CI) using the forward selection strategy. In the
153 saturated model, variables were maintained with results of $p < 0.05$ or that adjusted the
154 association measure by at least 10%, relevant to the outcome in question or that improved the
155 quality of the final model. Statistical analysis was performed using the statistical program
156 Stata® version 16.0 (College Station, Texas, USA).

157 This study is part of the matrix project entitled: Good Practices in Patient Care,
158 Infection Control and Processing of Health Products in the State of Rondônia, authorized by
159 the Ethics and Research Committee of the Federal University of Rondônia, CAE
160 20070719.5.0000.5300.

161 **Results**

162 There were 649 medical records analyzed, the incidence of confirmed endophthalmitis
163 was 11.94% (95% CI: 9.43;14.85) and probable endophthalmitis 10.88% (95% CI: 8.46;
164 13.70).

165 Half of the patients were female; most declared their skin color as brown or yellow
 166 and were over 60 years old (Table 1). Some patients already had a history of previous surgery
 167 (22.72%), used antibiotics (19.34%), more than half underwent bilateral surgery,
 168 approximately half of the users received the Eyeol® model intraocular lens.
 169 Table 1 – Characteristics of users undergoing Phacoemulsification with intraocular lens
 170 implantation, Porto Velho-RO, 2022 (n=649)

Variables	Total	Confirmed*		Likely**			
	n=649 %	Yes N=70	Not N=493	p- value	Yes N=86	Not N=493	p- value
Sex				0.81			0.08
Female	50.39	11.62	88.38		8.62	91.38	
Masculine	49.61	12.25	87.75		13.15	86.85	
skin color				0.42			0.04
White	26.66	9.15	90.85		5.70	94.30	
black	3.7	14.29	85.71		14.29	85.71	
brown and yellow	69.64	12.97	87.03		12.75	87.25	
age group				0.04			0.54
< 59 years old	18.64	16.81	83.19		7.84	92.16	
60 to 69 years	35.44	7.77	92.23		11.21	88.79	
> 70 years	40.92	13.11	86.89		11.79	88.21	
History of previous eye surgery				<0.01			<0.01
Not	77.28	14.84	85.16		13.58	86.42	
Yes	22.72	5.26	5.26		3.08	96.92	
used antibiotic				0.11			0.97
Yes	19.34	7.48	92.52		10.90	89.10	
Not	81.66	12.94	87.06		10.81	89.19	
bilateral surgery				<0.01			<0.01
Not	39.14	6.56	93.44		4.20	95.80	
Yes	60.86	15.79	84.12		15.54	84.46	

Lens Model – Eye 1				<0.01	<0.01
Oftcryl Asp Oft Vision	39.97	2.87	97.13	5.95	94.05
Eyeol	49.54	20.14	76.86	14.39	86.61
Mediphacos Ioflex	9.57	9.62	90.38	17.54	82.46
Alcon Type B crystal	0.93	16.67	83.33	-	100.00
Lens model - Eye 2				<0.01	0.02
Oftcryl Asp OftVision ®	31.39	6.96	93.04	7.76	92.24
Eyeol®	53.42	19.77	80.23	19.32	80.68
Mediphacos Ioflex®	14.94	20.00	80.00	18.37	81.63
Alcon Type B® Crystal	0.25	100.00	-	-	

171 * Confirmed in relation to those discarded.

172 ** Suspects in relation to discarded

173 Statistically significant differences were found for confirmed cases in relation to age
 174 group, history of previous ophthalmological surgery, bilateral surgery and lens model.
 175 Regarding probable cases, skin color, history of previous ophthalmic surgery, bilateral
 176 surgery, lens model and completion of the safe surgery checklist were statistically significant.

177 For confirmed cases, in the crude analysis, age between 60 and 69 years was a
 178 protective factor, as well as having a history of previous ophthalmologic surgery (Table 2).
 179 Having surgery in both eyes increased the chances of endophthalmitis 2.4 times and some
 180 lens models had a higher risk for endophthalmitis. In the adjusted analysis, bilateral surgery
 181 presented collinearity with the variable of confirmed cases, the use of the Eyeol lens remained
 182 as a risk factor in eye 1 and the Cristal Alcon Type B lens presented itself as a risk in use in
 183 eye 2.

184 Table 2 – Relative risk analysis of the characteristics of users undergoing Phacoemulsification
 185 with intraocular lens implantation, Porto Velho, Rondônia, Brazil, 2022 (n=649)

Variables	gross RR (CI95%)	Adjusted RR (95%CI)
-----------	---------------------	---------------------

Confirmed cases

Age		
60 to 69 years	0.46 (0.23; 0.89)	0.48 (0.21; 1.08)
> 70 years	0.77 (0.44; 1.36)	0.72 (0.37; 1.41)
History of previous eye surgery		
Yes	0.35 (0.16; 0.77)	0.63 (0.22; 1.77)
bilateral surgery		
Yes	2.40 (1.37; 4.20)	collinearity
Lens Model – Eye 1		
Eyeol®	7.02 (3.20; 15.39)	3.23 (1.27; 8.17)
Mediphacos Ioflex®	3.35 (1.06; 10.56)	2.34 (0.58; 9.38)
Alcon Type B® Crystal	5.8 (0.71; 47.21)	collinearity
Lens model - Eye 2		
Eyeol®	2.84 (1.31; 6.12)	1.21 (0.49; 2.97)
Mediphacos Ioflex®	2.87 (1.13; 7.28)	1.51 (0.56; 4.03)
Alcon Type B® Crystal	14.27 (1.79; 114.93)	16.14 (1.21; 214.42)
Probable Cases		
Sex		
Masculine	1.52 (0.92; 2.52)	1.88 (1.03; 3.44)
skin color		
black	2.51 (0.67; 9.26)	3.59 (0.70; 18.31)
brown and yellow	2.23 (1.10; 4.54)	2.78 (1.17; 6.60)
History of previous eye surgery		
Yes	0.22 (0.08; 0.62)	0.48 (0.15; 1.58)
bilateral surgery		
Yes	3.69 (1.88; 7.27)	collinearity
Lens Model – Eye 1		
Eyeol®	2.14 (1.33; 4.39)	1.33 (0.55; 3.19)
Mediphacos Ioflex®	2.94 (1.32; 6.56)	2.58 (0.91; 7.28)
Alcon Type B® Crystal	collinearity	-
Lens model - Eye 2		

Eyeol®	2.48 (1.19; 5.19)	1.97 (0.74; 5.25)
Mediphacos Ioflex ®	2.36 (0.93; 5.96)	1.55 (0.54; 4.40)
Alcon Type B® Crystal	-	-

186 * Adjusted for: age, history of previous eye surgery, bilateral surgery, and lens design.

187 ** Adjusted for: gender, skin color, history of previous eye surgery, bilateral surgery, and lens
188 design.

189 In relation to probable cases, in the crude analysis brown and yellow skin color was
190 presented as a risk factor. A history of ophthalmological surgery as a protective factor and the
191 use of Eyeol lenses in both eyes, Mediphacos Ioflex in eye 1 and Cristal Alcon Type B were a
192 risk factor for ophthalmitis. In the adjusted analysis, brown or yellow skin color remained
193 statistically significant and presented a risk 2.78 times (CI 95%: 1.17; 6.60) to develop
194 endophthalmitis, previous history of ophthalmic surgery showed collinearity and none lens
195 model showed significance

196 The average number of days between the date of the procedure and the date of
197 initiation of treatment was eight days (minimum of 1 and maximum of 38 days). Of the total
198 number of medical records evaluated, 97.69% had a consultation record up to 24 hours after
199 the surgical procedure, and of these, 73.50% had some sign or symptom (Table 3). In the
200 second consultation, 37.44% had symptoms, but in this second consultation, half of the
201 patients returned for evaluation of the procedure performed on the second eye. In the third
202 consultation 32.36% reported signs or symptoms, in the fourth consultation 19.88% and in the
203 fifth consultation 13.56%.

204 Table 3 – Frequency of signs and symptoms presented by time of return visit, Porto Velho,
205 Rondônia, Brazil, 2022 (n=649)

Signals and symptoms *	first consultat	second consultatio	Third consultat	Fourth appointm	Fifth Query
------------------------	--------------------	-----------------------	--------------------	--------------------	----------------

	ion (n=634)	n (n=392)	ion (n=485)	ent (n=185)	(n=99)
corneal edema	68.26	31.12	12.33	14.79	9.09
hypopyon	1.08	1.69	12.94	3.39	2.16
low visual acuity	1.08	1.69	13.71	3.39	1.39
conjunctival hyperemia	0.31	0.31	3.85	10.94	6.93
cloudy vitreous	-	-	-	0.15	-
eye pain	0.31	0.15	0.31	1.39	0.62
anterior chamber reaction	5.24	2.62	10.32	10.02	5.39
Others	3.39	2.47	15.72	10.94	6.47

206 * Patients may have presented more than one sign and symptom.

207 ** Other – the main symptoms recorded were inflammatory membranes, bullous keratopathy
208 and hyposphagma.

209 Of the total number of medical records evaluated, 21.91% collected biological
210 material. Three microorganisms were identified - *Pseudomonas luteola*, *Pseudomonas*
211 *oryzihabitans* and *Acinobacter baumannii* in the collections of vitreous and/or aqueous humor
212 (Table 4).

213 Table 4 - Microorganism identified according to culture of biological material, Porto Velho,
214 Rondônia, Brazil, 2022

microorganism	Vitreous humor	aqueous humor
<i>Pseudomonas luteola</i>	44	5
<i>Pseudomonas oryzihabitans</i>	two	1
<i>Acinobacter baumannii</i>	22	0
there was no growth	25	8
Result not found	42	61
Total*	135	75

215 *Some patients performed more than one collection

216 According to the records, of the total of 649 medical records, 12.17% indicated the use
217 of atropine, 14.79% prednisone, 17.57% vancomycin, 3.54% dexamethasone, 14.95%
218 amikacin, in addition to of other medications with less than 2% of registrations.

219 Discussion

220 Contrary to the world scenario, where the incidence of endophthalmitis is declining,
221 the incidence of postoperative endophthalmitis in Rondônia was 10.88%, a result much higher
222 than the incidence found in the literature, thus characterizing the largest outbreak of
223 endophthalmitis after cataract surgery ever registered in the world^[12,16,9].

224 Regarding demographic characteristics, a higher risk for endophthalmitis was found,
225 in probable cases, among males. This fact may be due to differences in the ocular flora or
226 variable adherence to postoperative care, which can increase complications in cataract
227 surgeries^[12,17,9].

228 When analyzing the skin color of the patients, the predominance of brown and yellow
229 presented itself as a risk factor of 2.78 times (CI 95%: 1.17; 6.60) for probable cases of
230 endophthalmitis when compared to people white skin. A study conducted in the United States
231 of America between 2010 and 2014 with more than 150,000 patients found higher rates of
232 endophthalmitis after cataract surgery among men, older individuals, African Americans and
233 Native Americans^[6].

234 Having surgery performed on both eyes increased the odds of endophthalmitis 2.4
235 times among probable cases. A systematic review conducted with 14 studies involving
236 276,260 people concluded that there is a lack of evidence on the cost-effectiveness of
237 performing ophthalmic procedures on the same patient on different days^[18].

238 The most common etiological agents identified in endophthalmitis after cataract
239 surgery are gram-positive, especially negative *coagulase* Staphylococcus, followed by gram-
240 negative and, less commonly, fungi^[19,20,21]. A systematic review of studies conducted in India
12

241 found that the most common microorganisms in endophthalmitis after cataract surgery were
242 Staphylococcus, followed by Gram-negative bacilli of *Pseudomonas* species^[15]. In our study,
243 there was a predominance of gram-negative being among the main ones: *Pseudomonas*
244 *luteola*, *Pseudomonas oryzihabitans* and *Acinobacter baumannii* in the collections of vitreous
245 and/or aqueous humor. This fact is also found in two studies conducted in Asia^[5,22]. However,
246 endophthalmitis caused by other species such as *Pseudomonas oryzihabitans*, *Pseudomonas*
247 *stutzeri*, and *P. luteola* are rare, and the first case of endophthalmitis caused by *P. luteola* was
248 reported in Asia in 2018^[23].

249 The occurrence of contamination by microorganisms can be associated with
250 different causes, such as, for example, contamination of the ocular viscoelastic device^[19],
251 vials used in surgeries^[24], pre-filled syringes of saline solution^[25]. Or it may be related to the
252 surgeon's experience^[6], number of surgeries performed^[6] and failures in work processes, with
253 emphasis on the inadequate processing of surgical instruments^[4].

254 The main clinical manifestation of endophthalmitis was corneal edema with a
255 proportion of 68.26% patients, in the first consultation after the surgical procedure, followed
256 by hypopyon, low acuity, conjunctival hyperemia, ocular pain, anterior chamber reaction and
257 other symptoms. Eye pain and hypopyon occur in up to 75% of clinical manifestations of
258 endophthalmitis after cataract surgery^[5,22].

259 The average number of days between the date of the procedure and the date of
260 treatment initiation was eight days, a result similar to that reported in the literature^[5,26,27]. In
261 addition, within this period, there must be availability for the patient's prompt care at any
262 time, in case of need^[5]. Most complications after cataract surgery occur in the late
263 postoperative period, which reinforces the importance of actively seeking out patients after
264 the procedure, even in cases of joint efforts - which does not always occur in this type of care
265 in Brazil^[13].

266 The conduct of using atropine, prednisone, vancomycin, dexamethasone and amikacin
267 is in accordance with the literature, as it is recommended that the treatment of endophthalmitis
268 be based on the selection of effective and safe antimicrobials. A broad-spectrum therapy for
269 gram-positive and gram-negative organisms, such as vancomycin and intravitreal ceftazidime
270 or amikacin, is initially suggested.

271 In order to avoid the adverse event, there are some registered preventive actions for
272 endophthalmitis, such as the use of 0.66% povidone-iodine eye drops before surgery^[28]. Or
273 use of intracameral antibiotics during surgical procedures^[29,21] can be considered as a
274 preventive approach to infections.

275 Among the limitations of this study is the fact that it was not possible to verify
276 potential sources of infection such as instruments, lenses, surfaces or others. The data used in
277 this study was taken from the medical records filled out by the professionals hired for the task
278 force, which may have flaws in filling in information and defining cases due to the absence of
279 requests for microorganism culture tests, for example. Another limitation was the fact that it
280 was not possible to verify how postoperative care was given by the patients themselves in
281 their homes.

282 As this is the largest outbreak of endophthalmitis ever recorded in the world, it is
283 understood that the results are useful to draw attention mainly to the need for specific
284 protocols for contracting, carrying out and monitoring care services of the joint effort type of
285 cataract surgeries, common practice mainly in regions with little access to health services.

286 During the outbreak investigation, all professionals involved in the task force were
287 interviewed by the state health surveillance team. These interviews were transcribed and will
288 be analyzed to find flaws in the process of conducting surgeries in all its stages - pre, peri and
289 post aiming at creating mechanisms that can regulate the occurrence of joint efforts for
290 cataract surgeries, as well as promoting the training of health care professionals involved

291 directly with patient care or indirectly as in the preparation of instruments used in the
292 procedure and health surveillance professionals responsible for monitoring the actions carried
293 out by health institutions.

294 **References**

- 295 1. Almança ACD, Jardim SP, Duarte SRMP. Epidemiological profile of the patient
296 undergoing cataract surgery. Rev. bras.oftalmol [Internet]. 2018. Available from:
297 <https://doi.org/10.5935/0034-7280.20180055>
298
- 299 2. Luz RA, Dall'Oglio LPS, Silva FS, Ghirelli W, Padoveze MC. Endophthalmitis after
300 cataract surgery: results from seven years of epidemiological surveillance. Rev Bras
301 Oftalmol [Internet]. 2019. Available from: [https://doi.org/10.5935/0034-](https://doi.org/10.5935/0034-7280.20180102)
302 [7280.20180102](https://doi.org/10.5935/0034-7280.20180102).
303
- 304 3. Teles LPM, Passos MA, Teles COM, Lima SO. Analysis of quality of life before and
305 after cataract surgery with intraocular lens implantation. Rev. Bras. Oftalmol.
306 [Internet]. 2020. Available from: <https://doi.org/10.5935/0034-7280.20200052>
307
- 308 4. Brazil. National Health Surveillance Agency. Endophthalmitis and Toxic Anterior
309 Segment Syndrome Prevention Measures Related to Invasive Ophthalmologic
310 Procedures/National Health Surveillance Agency. Brasília: Anvisa, 2017. Available
311 from:
312 [http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=%2FRpSXbEAlp](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=%2FRpSXbEAlpQ%3D)
313 [Q%3D](http://www.riocomsaude.rj.gov.br/Publico/MostrarArquivo.aspx?C=%2FRpSXbEAlpQ%3D)
314

- 315 5. Sun J, Guo Z, Li H, Yang B, Wu X. Acute infectious endophthalmitis after cataract
316 surgery: epidemiological features, risk factors and incidence trends, 2008-2019. *Infect*
317 *Drug Resist* [Internet]. 2021. Available from: <https://doi.org/10.2147/IDR.S304675>
318
- 319 6. Schmier JK, Hulme-Lowe CK, Covert DW, Lau EC. An updated estimate of costs of
320 endophthalmitis following cataract surgery among Medicare patients: 2010-2014. *Clin*
321 *Ophthalmol* [Internet]. 2016 Oct 26; 10:2121-2127. doi: 10.2147/OPHTH.S117958.
322 PMID: 27822008; PMCID: PMC5087791
323
- 324 7. Soare SD, Ilie L, Costeliu O, Ghiță AC, Voinea LM, Ghiță AM. Ocular surface
325 bacterial surgery and its management in the prophylaxis of endophthalmitis after
326 cataract surgery. *Romanian Society of Ophthalmology* [Internet]. 2021. Available
327 from: <https://doi.org/10.22336/rjo.2021.2>
328
- 329 8. Ma, W, Hou G, Wang J, Liu T, Tian F. Evaluation of the effect of gentamicin in
330 surgical perfusion solution on cataract postoperative endophthalmitis. *BMC*
331 *Ophthalmol* [Internet] 2022. Available from: [https://doi.org/10.1186/s12886-022-](https://doi.org/10.1186/s12886-022-02633-2)
332 [02633-2](https://doi.org/10.1186/s12886-022-02633-2)
333
- 334 9. Nowak MS, Grzybowski A, Michalska-Matecka K, Szaflik JP, Koziół M, Niemczyk
335 W, Grabska-Liberek I. Incidence and Characteristics of Endophthalmitis after Cataract
336 Surgery in Poland, during 2010–2015. *Int. J. Environ. Res. Public Health* [Internet].
337 2019. 16(12), 2188. Available from: <https://doi.org/10.3390/ijerph16122188>
338
- 339 10. Kim SH, Yu MH, Lee JH, Kim SW, Rah SH. Endophthalmitis after Cataract Surgery
340 in Korea: A Nationwide Study Evaluating Incidence and Risk Factors in a Korean
341 Population. *Yonsei Med J* [Internet]. v. 60, n. 5, p. 467-473. 2019. Available from:
342 <https://doi.org/10.3349/ymj.2019.60.5.467>
343
- 344 11. Pershing S, Lum F, Hsu S, Kelly S, Chiang MF, Rich WL, Parke DW.
345 Endophthalmitis after Cataract Surgery in the United States A Report from the
346 Intelligent Research in Sight Registry, 2013- 2017. Elsevier by American Academy of
347 Ophthalmology [Internet]. V. 127, n. 2, p. 151-158. 2020. Available from:
348 <https://doi.org/10.1016/j.ophtha.2019.08.026>
349
- 350 12. Wai YZ, Fiona Chew LM, Mohamad AS, Ang CL, Chong YY, Adnan TH, Goh PP.
351 The Malaysian cataract surgery registry: incidence and risk factors of postoperative
352 infectious endophthalmitis over a 7-year period. *Int J Ophthalmol* [Internet]. 2018.
353 doi: 10.18240/ijo.2018.10.17. PMID: 30364221; PMCID: PMC6192968.
354
- 355 13. Meirelles MGB, Santana TS, Vieira LTQ, Costa CSC, Celestino KAA, Abud MB,
356 Ávila MP. Prevalence of cataract surgery complications in a health care campaign.
357 *Braz. J. Develop.* [Internet]. 2020 6(7):53783-90. Available from:
358 <https://ojs.brazilianjournals.com.br/ojs/index.php/BRJD/article/view/14244>
359
- 360 14. Brazil. Brazilian Institute of Geography and Statistics. Directorate of Research,
361 Coordination of Population and Social Indicators. Resident population estimates with
362 reference date July 1, 2021. Brasília, DF. 2021. Available from: <https://ibge.gov.br>.
363

- 364 15. Lalitha P, Sengupta S, Ravindran RD, Sharma S, Joseph J, Ambiya V, Das T. A
365 literature review and update on the incidence and microbiology spectrum of
366 postcataract surgery endophthalmitis over past two decades in India. *Indian J*
367 *Ophthalmol* [Internet]. 2017. 65(8):673-677. Available from:
368 https://doi.org/10.4103/ijo.IJO_509_17
369
- 370 16. Rahmani S, Elliott D. Postoperative endophthalmitis: a review of risk factors,
371 prophylaxis, incidence, microbiology, treatment, and outcomes. *Semin Ophthalmol*
372 [Internet]. 2018. 33:95–101. Available from:
373 <https://doi.org/10.1080/08820538.2017.1353826>
374
- 375 17. Hashemian H, Mirshahi R, Khodaparast M, Jabbarvand M. Post-cataract surgery
376 endophthalmitis: Brief literature review. *J Curr ophthalmol* [Internet]. 2016. 28(3),
377 101–105. Available from: <https://doi.org/10.1016/j.joco.2016.05.002>
378
- 379 18. Dickman MM, Spekrijse LS, Winkens B, Schouten JSAG, Simons RWP, Dirksen
380 CD, Nuijts RMMA. Immediate sequential bilateral surgery versus delayed sequential
381 bilateral surgery for cataracts. *Cochrane Database of Systematic Reviews* [Internet].
382 2022. Available from: <https://doi.org/10.1002/14651858.CD013270.pub2>
383
- 384 19. Yoon SJ, Kim SH, Bahk HJ, Ahn YS, Lee JJ, Kim HJ, Lim HJ, Choi MJ, Shin JH,
385 Lee YK. Fungal Endophthalmitis Outbreak after Cataract Surgery, South Korea, 2020.
386 *Emerg Infect Dis* [Internet]. 2022. 28(11):2226–33 Available from:
387 <https://doi.org/10.3201/eid2811.220361>
388
- 389 20. Durand ML. Bacterial and fungal endophthalmitis. *ClinMicrobiol Rev* [Internet].
390 2017. 30:597–613. Available from: <https://doi.org/10.1128/CMR.00113-16>
391
- 392 21. Malmin A, Syre H, Ushakova A, Utheim TP, Forsaa VA. Twenty years of
393 endophthalmitis: Incidence, aetiology and clinical outcome. *Acta Ophthalmol*
394 [Internet]. 2021. 99(1): e62-e69. Available from: <https://doi.org/10.1111/aos.14511>
395
- 396 22. Gower EW, Keay LJ, Stare DE, Arora P, Cassard SD, Behrens A, Tielsch JM, Schein
397 OD. Characteristics of Endophthalmitis after Cataract Surgery in the United States
398 Medicare Population. *Ophthalmology* [Internet]. 2015. 122(8):1625-32. Available
399 from: <https://doi.org/10.1016/j.ophtha.2015.04.036>
400
- 401 23. Naik AU, Jaya Prakash V, Susvar P, Therese KL, Parameswari CK. Postoperative
402 endophthalmitis due to *Pseudomonas luteola*:
403 First reported case of acute and virulent presentation from a tertiary eye care
404 center in South India. *Indian J Ophthalmol* [Internet]. 2018. 66:1200-2. Available
405 from: https://doi.org/10.4103/ijo.IJO_242_18
406
- 407 24. Mikosz CA, Smith RM, Kim M, Tyson C, Lee EH, Adams E, et al.; Fungal
408 Endophthalmitis Outbreak Response Team. Fungal endophthalmitis associated with
409 compounded products. *Emerg Infect Dis* [Internet]. 2014. 20:248–56. Available from:
410 <https://doi.org/10.3201/eid2002.131257>
411
- 412 25. Brooks RB, Mitchell PK, Miller JR, Vasquez AM, Havlicek J, Lee H, et al.
413 *Burkholderia cepacia* Workgroup. Multistate outbreak of *Burkholderia cepacia*

- 414 complex bloodstream infections after exposure to contaminated saline flush syringes:
415 United States, 2016–2017. *Clin Infect Dis* [Internet]. 2019. 69:445–9. Available from:
416 <https://doi.org/10.1093/cid/ciy910>
417
- 418 26. Jabbarvand M, Hashemian H, Khodaparast M, Jouhari, M, Tabatabaei A, Rezaei, S.
419 Endophthalmitis occurring after cataract surgery: outcomes of more than 480 000
420 cataract surgeries, epidemiologic features, and risk factors. *Ophthalmology* [Internet].
421 2016. 123(2):295–301. Available from: <https://doi.org/10.1016/j.ophtha.2015.08.023>
422
- 423 27. Ledbetter EC, Spertus CB, Kurtzman RZ. Incidence and characteristics of acute-onset
424 postoperative bacterial and sterile endophthalmitis in dogs following elective
425 phacoemulsification: 1,447 cases (1995–2015). *J Am Vet Med Assoc* [Internet]. 2018.
426 253(2):201–208. Available from: <https://doi.org/10.2460/javma.253.2.201>
427
- 428 28. Musumeci R, Troiano P, Martinelli M, Piovella M, Carbonara C, Rossi S, Alessio G,
429 Molteni L, Molteni CG, Saderi L, Sotgiu G, Cocuzza CE. Effectiveness of 0.66%
430 Povidone-Iodine Eye Drops on Ocular Surface Flora before Cataract Surgery: A
431 Nationwide Microbiological Study. *J Clin Med* [Internet]. 2021. 19;10(10):2198.
432 Available from: <https://doi.org/10.3390/jcm10102198>
433
- 434 29. Wang XL, Huang XY, Wang Z, Sun W. The Anterior Chamber Injection of
435 Moxifloxacin Injection to Prevent Endophthalmitis after Cataract Surgery: A Meta-
436 analysis. *J Ophthalmol* [Internet]. 2020. 25;2020:7242969. Available from:
437 <https://doi.org/10.1155/2020/7242969>